BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 9000632)

  • 1. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
    J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
    J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
    Ren J; Esnouf R; Hopkins A; Ross C; Jones Y; Stammers D; Stuart D
    Structure; 1995 Sep; 3(9):915-26. PubMed ID: 8535785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
    Hsiou Y; Das K; Ding J; Clark AD; Kleim JP; Rösner M; Winkler I; Riess G; Hughes SH; Arnold E
    J Mol Biol; 1998 Nov; 284(2):313-23. PubMed ID: 9813120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
    J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution.
    Ding J; Das K; Hsiou Y; Sarafianos SG; Clark AD; Jacobo-Molina A; Tantillo C; Hughes SH; Arnold E
    J Mol Biol; 1998 Dec; 284(4):1095-111. PubMed ID: 9837729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
    Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
    FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.
    Hsiou Y; Ding J; Das K; Clark AD; Hughes SH; Arnold E
    Structure; 1996 Jul; 4(7):853-60. PubMed ID: 8805568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
    Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
    J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
    Boyer PL; Ding J; Arnold E; Hughes SH
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1909-14. PubMed ID: 7529011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.
    Freitas RF; Galembeck SE
    J Phys Chem B; 2006 Oct; 110(42):21287-98. PubMed ID: 17048958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
    Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
    J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
    Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
    Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
    Pelemans H; Esnouf RM; Jonckheere H; De Clercq E; Balzarini J
    J Biol Chem; 1998 Dec; 273(51):34234-9. PubMed ID: 9852086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.
    Ding J; Das K; Tantillo C; Zhang W; Clark AD; Jessen S; Lu X; Hsiou Y; Jacobo-Molina A; Andries K
    Structure; 1995 Apr; 3(4):365-79. PubMed ID: 7542140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.
    Esnouf RM; Stuart DI; De Clercq E; Schwartz E; Balzarini J
    Biochem Biophys Res Commun; 1997 May; 234(2):458-64. PubMed ID: 9177293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
    Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Stammers DK
    J Mol Biol; 2004 Feb; 336(3):569-78. PubMed ID: 15095972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
    Taylor PB; Culp JS; Debouck C; Johnson RK; Patil AD; Woolf DJ; Brooks I; Hertzberg RP
    J Biol Chem; 1994 Mar; 269(9):6325-31. PubMed ID: 7509800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.